RNAi and Age-Related Macular Degeneration

Another application for gene silencing has been wet and dry macular degeneration, which a team of researchers from a range of institutions including the Shiley Eye Institute at the University of California, San Diego, has been studying. The article is HERE.

Age-related macular degeneration is currently the leading cause of blindness among people over the age of 65 and currently affects approximately 10 million people in the U.S. alone. There are two versions of the disease—dry and wet degeneration, but both involve the degradation of the center of the retina called the macula which eventually causes blindness from the center of the eye, outward. Dry macular degeneration is the most common form of the disease, in which cells in the macula slowly die off.
However, a team of clinicians from several institutions including the Shiley Eye Institute and lead by Kang Zhang, a professor of ophthalmology, have recently discovered a genetic link associated with dry macular degeneration. The genetic expression the team identified involves a molecule that assists in the body’s immune response. The molecule, known as tlr3, is triggered by the emergence of RNA that is typically in the form of invading viruses. The molecule’s job is to invade and destroy infected cells in order to prevent further spread of the virus. The problem lies in the over-expression of this molecule which causes it to kill too many cells with the mildest indicator of an intruder, thus increasing the risk for macular degeneration.
Currently, RNAi therapies targeting wet macular degeneration are underway and Zhang’s team is observing them intently. Researchers working on the wet macular degeneration are attempting to isolate a different gene that may cause an overgrowth of blood vessels behind the retina. Since tlr3 is triggered by RNA, Zhang is concerned that the RNAi therapies used to suppress the overgrowth of blood vessels may actually end up triggering the tlr3 molecules in people with a higher genetic variant for it, in which the tlr3 would end up destroying more retinal cells and further degrade vision.
As Zhang’s team strives to develop therapies to treat dry macular degeneration, they also want to explore how the tlr3 molecule reacts in patients with wet macular degeneration and RNAi treatment. Some researchers believe that the molecule will have no effect on RNAi, while others think that the combination of RNAi suppression of blood vessel growth and the cell destruction of tlr3 will cancel each other out and no effect will take place.
In order for the RNAi therapies for macular degeneration to be successfully implemented in our healthcare system, more trials are needed. For example, if patients with a higher propensity for the tlr3 molecule experience adverse effects to the RNAi treatment for wet macular degeneration, then a regulation process must be established to prevent treatment in the wrong people. This could mean screening patients to see if they possess the variant for tlr3 and depending on their results, they would either undergo the RNAi treatment or not, depending on their genotype. This type of additional screening and testing drives up costs considerably and shows how complicated it could be to incorporate RNAi treatments in our future healthcare system due to the wide range of variables.

Rnai therapy+personalized medicine=the future

With the future looking forward to utilizing the therapeutic powers of rnai, this new therapy has to be made personalized. After all we are talking about silencing genes. Different people have different genetic make ups and hence these interferences will have to designed on an indivisual basis especially when we talking about diseases caused by multiple gene interactions.
Personalized medicine- a hot topic in current healthcare debate- has the following isues associated with it. First we have the economic aspect- is it going to be worth all the time and effort? Is it going to be affordable? Second- what market are we catering to? Third- will insurance companies cover this new approach? The answers to these questions lie as much in the future as the therapy itself. We cannot tell. What we do know is that it s definitely going to be expensive, affordable by only a few and insurance might cover it. However when one analyses the situation, the potential benefits greatly outweigh the risks involved. "RNAi has an unbelievable potential to manage genetic diseases and treat them," said Steven Dowdy, PhD, Howard Hughes Medical Institute Investigator and professor of cellular and molecular medicine at UC San Diego School of Medicine. "While there's still a long way to go, we have successfully developed a technology that allows for siRNA drug delivery into the entire population of cells, both primary and tumor-causing, without being toxic to the cells."
Especially in the case of genetic disorders, where nothing works better than personalized medicine, as of now, Rnai is all we have the table. To view more articles on personalized medicine and its future check out the link below:
http://www.personalizedmedicine.com/articles.php

RNA silencing… or activation? A look on a potential breakthrough in the world of RNAi

The RNA revolution began in 1998 with the discovery that dsRNA could turn off specific genes in roundworms. So far, over 500 miRNA sequences that can be used for interference have been identified in the human genome. But now, it seems that a couple researchers have found a whole new side to the growing world of RNAi.

http://www.nature.com/nature/journal/v448/n7156/full/448855a.html

Dr. Li stumbled upon RNA activation while working on DNA methylation. These chemical tags often silence nearby genes when added to a region of the DNA. Li was attempting to control (and downregulate) the methylation of genes encoding for a tumour-suppressing protein, E-cadherin. He added dsRNA strands complementary to the promoter region of these genes to prostate cancer cell cultures. The promoter sequence enables the expression of the gene it is associated to – in this case, regulates the synthesis of E-Cadherin. What he found was extraordinary: the experiment had actually boosted levels of E-Cadherin in the cell cultures by 4 to 14-fold, thus enhancing the expression of the gene in question.

Growing evidence with other cancer-related genes strengthened the plausibility of this new mechanism. While working with Place, Li found that activation used some of the same key proteins as the silencing pathway, such as Dicer. He was able to fine-tune the level of activation by simply changing the RNA sequence slightly. Finally, Place and Li were able to successfully design miRNA strands that could be used for activation of specific genes such as those for E-Cadherin expression. All this evidence supported the idea that miRNA could use the interference pathway to activate genes.

In the scientific world, the idea of activation has been met with much skepticism. Despite repeated attempts to publish their findings, Place and Li’s paper was only accepted in the Proceedings of the National Academy of Science in August 2006. Without clear knowledge of the mechanism and evidence to support it, their results were considered unconvincing by much of the scientific community. The idea of activation may be struggling because of its fundamental contradiction with the interference dogma.

There have been multiple theories devised to explain the mechanism behind activation. According to some, it may simply be a form of inhibition in disguise, due to the accidental blocking of another silencing RNA or downregulating DNA protein. However, the specificity and predictability of RNA activation through promoter targetting seems to reject that hypothesis. RNA activation also seems to proceed with very different kinetics, taking days to appear but lasting weeks while silencing is usually triggered within hours but ceases after about a week. This reinforces the belief that RNA activation operates directly at the gene-promoter region of the DNA, meaning that the RNA strand would have to sneak into the cell nucleus where DNA is transcribed in order to operate.

While the mechanism of RNA activation and its range of effectiveness are still under investigation, there is no doubt that this new discovery will completely turn around the world of RNA interference and its associated therapeutic applications. One can imagine RNA activation to be used in gene therapy, to upregulate the expression of vital genes in diseased individuals. Enhancing the expression of genes coding for immune cells for treatment of SCID (Severe Combined Immunodeficiency), or of genes coding for tumour-repressing proteins for cancer patients (as done by Li) are two examples of tremendous medical applications that could be brought on by RNA activation.

Improving siRNA efficiency!

The use of RNA interference to silence specific disease-related genes is still inchoate and far from being used as a therapy, but scientists are working hard to speed up the process. Even though several in vitro and small animals tests have been performed, the precision and efficiency of siRNA as treatment is still not sufficient to use in humans. For example, there are still many issues when it comes to safely delivering the siRNA--- it cannot be simply injected into the body. Even though current researchers have been using virus-based vectors to deliver siRNA, one must keep in mind that there are risks attached to this method. There is the possibility that the virus becomes active; then the solution to one problem will be overshadowed by the creation of another. Moreover, the researchers must accurately determine the amount of siRNA that will be administered because a slightly deviation from the needed amount could trigger an immune response.
As it seems, there are still many details to figure out before using siRNA in the human body. However, Abe, N., Abe, H. & Ito, Y in their paper “Dumbbell-shaped nanocircular RNAs for RNA interference” demonstrated a way to solve one of the many roadblocks to efficient and precise siRNA delivery.
The enzymes in the body that attack the foreign natural RNA starts degrading the RNA at the loose ends. Therefore, in order to prevent this or delay the degradation, they decided to create dumbbell shaped RNAs. One issue with this alteration of the RNA shape was that they still needed Dicer, the enzyme that cleaves the RNA into siRNA, to recognize the RNA. Fortunately, studies showed that Dicer had no problem recognizing the dumbbell shaped RNAs. Finally, the dumbbell shaped RNAs proved to be more efficient than linear RNA in creating siRNA in both effectiveness and resistance. Therefore, this study demonstrates that slowly the barriers to using siRNA efficiently are being brought down and that, in the future, siRNA could be used safely in humans.
For more information, look at the following:
http://www.innovations-report.com/html/reports/life_sciences/report-104114.html

and

http://pubs.acs.org/doi/full/10.1021/ja0754453?cookieSet=1

A new improved gene therapy?

As written in one of the previous posts, treating neurodegenerative diseases with RNAi is more difficult than treating hepatitis C or other similar diseases. However, a new study on the neurodegenerative disease Machado-Joseph, shows that an improved gene therapy is being tested.
What is Machado-Joseph disease and why is it important?
Finding a cure for Machado-Joseph disease is important because at present it is untreatable. The disease is characterized by progressive motor discoordination that could, eventually, lead to death.
The MJD1 gene is responsible for the production of ataxin-3 ---a brain protein alleged to be useful in the destruction of toxic proteins in the brain. However, the mutated MJD1 gene is not able to produce functional ataxin-3 protein. The mutated ataxin-3 protein then accumulates in the brain and causes neural damage.
This research conducted by Alves, Almeida, Déglon et al. from the Center for Neurosciences & Cell Biology at the University of Coimbra, Portugal and the Institute of Molecular Imaging and Molecular Imaging Research Center in Orsay, France have found an improved way to silence the MJD1 mutated gene and potentially treat Machado-Joseph disease.
Nevertheless, how exactly is this different from any other studies? Even though the study still uses RNAi to silence the gene, these researchers have improved their targeting precision. Remember, that there are usually two copies of a gene--- the mutated and the normal gene. Therefore, if only one gene is mutated and the other MJD1 gene is still producing normal ataxin-3, it would be deleterious to silence both the mutated and normal MJD1 gene.
The improved RNAi has been tested on infected rats with the neurodegenerative disease. The study showed that the RNAi led to a decrease of approximately 50% of the mutated proteins accumulated in the brain of a live animal.
However, we must keep in mind that even though these results are promising, they are promising in rats. Further research has to be done before moving to clinical trials. On the bright side, the RNAi treatment did not cause any side effects in the tested rats; therefore, decreasing the possibility of having serious side effects in humans. In conclusion, this experiment provides hope that one day RNAi will be used to treat neurodegenerative diseases by silencing the mutated gene and not the normal gene that can still be useful in the brain.
For more information, check out: http://www.innovations-report.com/html/reports/life_sciences/a_improved_gene_therapy_treatment_machado_joseph_119799.html

RNAi delivery system crosses blood-brain barrier to target brain cancer

picture: the blood brain barrier


As seen in many of the articles above, Two fundamental difficulties in the delivery of drugs to treat central nervous system (CNS) diseases are the systemic delivery of therapeutics across the bloodbrain-barrier (BBB), and the targeting of drugs to specific tissues or cells within the brain. With the advent and promise of RNA-based therapeutics that utilize RNA interference (RNAi) to trigger specific silencing of genes within diseased tissues, the necessity to surmount such obstacles has become even more urgent. Most pre-clinical and clinical studies on delivery of RNAi to the CNS have utilized invasive, intra-cerebral delivery of RNA to the targeted tissue. Thus, methods need to be developed to facilitate delivery of therapeutically significant quantities of RNA to the CNS via the systemic route, and to elicit clinically significant RNAi effects within the CNS tissues.
One of the approaches developed to overcome this obstacle is using antibody keys to pass through both the blood brain barrier and the tumor cell membrane with the help of liposomes which deposit a genetically engineered non-viral plasmid in the brain cancer cells. The plasmid encodes a short hairpin RNA (shRNA) designed to interfere with the expression of the epidermal growth factor receptor, EGFR, a potent proponent of tumor cell proliferation. This works just like a Trojan horse. The liposome acts as the hollowed horse; the plasmid is the Trojan warrior released inside the cell to combat the cancer.
Pre clinical studies on mice have shown encouraging results. Tumors in the treated mice had reduced EGFR content, and the mice showed an 88 percent increase in survival time. With continued research and new discoveries, it won’t be too long before the problem of delivery is resolved.
For further information check out the article below:
http://www.innovations-report.com/html/reports/medicine_health/report-29779.html

How far is RNAi from the neurology clinic?

With all this talk about RNAi, where do we stand currently? There is potential to treat several diseases with RNAi but how far have we progressed? For conditions like age-related macular degeneration, respiratory syncytial virus and hepatitis C infection, several human phase and II therapeutic RNAi trials have already been completed or are nearing completion. However, none of these early trials have targeted a brain disease.
So what is so different when it comes to these neurodegenerative disorders? Perhaps the biggest challenge facing the field of RNAi research is achieving safe and efficient delivery of therapeutic RNAi agents to neurons—highly specialized, postmitotic cells protected by the blood-brain barrier. The chronic nature of many brain disorders also means that sustained delivery of an RNAi reagent, or its repeated administration, will be required to achieve a long-term benefit. Furthermore these diseases are not attributable to single genetic defect which makes RNAi therapy difficult.

But even before we think of carrying out human trails the chosen strategy will need to undergo preclinical testing in validated animal models. The first successful RNAi trial for a neurodegenerative disease was completed in a transgenic mouse model of Spinocerebellar ataxia (SCA) type1. SCA1 is a dominantly inherited polyglutamine expansion disorder, the mutant ataxin-1 protein acts via a toxic, gain-of-function mechanism that causes neuronal dysfunction and cell death in the cerebellum and certain brainstem nuclei. Mice lacking the Atxn1 gene show only subtle behavioral abnormalities, suggesting that RNAi-mediated knockdown of both alleles in humans would be unlikely to result in adverse effects caused by loss of gene function.
Since the first report of successful therapeutic RNAi in SCA1 mice, many successful preclinical trials in mouse models of other neurodegenerative diseases such as familial ALS (SOD1), familial PD (α-synuclein), and HD (huntingtin) have been completed and have had their results published. These trials have used different RNAi effector molecules, explored various delivery methods (mostly virus-mediated delivery), and targeted diverse anatomical areas ranging from the hippocampus to motor neurons and muscle.
While initial studies in cellular and animal models of neurodegenerative disease have produced encouraging results, the safety of this therapy in the diseased human CNS has not, however, been established. Whether RNAi therapy is an effective way to treat incurable neurodegenerative diseases?!...only the future can tell! As of now all we can say is that there is potential.
The following article discusses how far RNAi therapy is from the neurology clinic:
http://www.medscape.com/viewarticle/559503

Inhibition of Monkeypox virus replication and application to RNAi control of viral diseases

The use of RNAi pathway as a new antiviral approach is promising because viruses have relatively small genomes with a limited number of targetable genes. Recent studies utilized RNAi to silence specific viral genes. This allows not only a precise identification of the function of viral genes, but also to inhibit viral replication.

http://www.virologyj.com/content/6/1/188

The following article examined how RNAi could be used to inhibit the activity of Monkeypox virus (MPV), a member of the Poxviridae family comprising several other human pathogens such as cowpox (CPXV), Vaccinia (VACV) and Variola (VARV). These pathogens have been known to cause human diseases with various severity, ranging from mild conditions to death in the most severe cases. Monkeypox virus is believed to have been circulating for a long time in host animals, but only recently has person-to-person transmission been reported. Monkeypox disease manifestation is similar that of smallpox but MPV is less lethal to the host. Treatment against poxviruses may become a priority as most of the young population is completely immune naïve and a natural or deliberate release of these viruses constitutes a serious threat to public health. Although antiviral drugs such as Cidofovir exist, their effectiveness may erode with emergence of resistant viral strain and limiting side effects. The need for novel therapeutic strategies against such viruses are paramount, and RNAi could prove to be at the forefront in solving this challenge.

In their study, the researchers selected 12 viral genes based on genome-wide expression studies and developed numerous siRNA constructs. These constructs were evaluated for their ability to inhibit viral replication in vitro. The inhibition of viral replication varied significantly based on the targeted gene and the concentration of siRNA used. The siRNA constructs targeting the respective essential genes for viral replication (A6R) and viral entry (E8L) inhibited viral replication in cell culture by up to 95% without any cytotoxic side effects. While both constructs showed increasing antiviral activity with concentration, A6R constructs showed complete inhibition at lower concentration. This emphasized the central role of the A6R gene for viral replication.
Also of importance is the time scale of their usefulness. Effectiveness of RNAi occurs for only short periods of time mainly due to the relatively short half life of siRNA and the lack of an amplification mechanism in mammalian cells. It appears that the siA6 constructs remained active and kept viral replication rate at less than half its value for over a week, indicating the unusual stability of these constructs in vitro.
Through these observations, siA6 appears to a good candidate for the treatment of Monkeypox. Successful siRNA application in the treatment of diseases depends mainly on the two parameters analyzed above, namely stability of the siRNA and efficacy against a high viral burden.

This study illustrated the great disparity in siRNA efficacy among different targeted gene pools. Because the exact mechanisms for this disparity are unknown, identifying the effectiveness of an siRNA empirically remains necessary in order to assess the therapeutic application of RNAi. The authors also observed a variation in the efficacy of siRNA targeting for the same gene pool, most likely due to intra-cellular mechanisms altering the targeted RNA sequences and preventing the RNAi complex from identifying its viral target.

The identification of stable and efficacious siRNA probes in the inhibition of viral activity is a first and decisive step in moving towards therapeutic applications of RNAi for viral diseases. The advantages over traditional, chemically synthesized antiviral drugs are numerous: not only would RNAi allow for precise and targeted inhibition of viral growth, but also the flexibility to readapt siRNA molecules to target emerging resistant viral strains. Although more research must be conducted on the in vitro efficacy and stability of siRNA constructs before they can be applied to human subjects, RNAi therapy for viral disease control shows much promise.

Understanding the mechanics of RNA silencing

The introduction of double-stranded RNA (dsRNA) can elicit a gene-specific RNA interference response in a variety of organisms and cell types, effectively preventing the transcription, or “silencing” the target genes. This formidable phenomenon has lead to the development of a whole new research field, with unbounded potential for treatment of various autoimmune and infectious diseases. Once inside cells, long dsRNA molecules are cleaved into double-stranded small interfering RNAs (siRNAs) by a Dicer enzyme. This is the earliest step in the RNAi silencing mechanism. siRNAs are long enough to mediate sequence-specific mRNA cleavage, silencing the transcription of the corresponding gene.

http://www.molbiolcell.org/cgi/content/abstract/14/7/2972

The following article expands upon the basic findings of RNA interference by Craig Mello and Andrew Fire. Although we have a general model for cellular uptake of dsRNA responsible for silencing, the specific mechanisms involved are unclear. The model does not account for the variability in efficacy of RNA silencing between different cells type. Also, the mechanisms behind the systemic nature of the interference response, meaning how RNA silencing spreads to regions away from the site of dsRNA delivery, are unknown. Incidentally, genetic variability can influence the extent of RNA silencing in organisms, and more specifically, the trafficking of RNA silencing signals. This has an impact when considering RNA interference as a treatment method. Indeed, the variability of response to RNAi therapy within a population would mean implementing more personalized and expensive treatments down the line.

To illustrate the versatility of this RNA interference pathway, the article points out four distinct methods for delivery of dsRNA into an organism: injection into a given site, feeding the organism with bacteria engineered to express dsRNA, soaking the organism in dsRNA, and finally in vivo transcription of dsRNA from transgene promoters. This article specifically assessed the ability of in vivo-delivered dsRNA to elicit systemic (global) RNA silencing. This was done by introducing transgenes that expressed dsRNA under the direction of tissue-specific promoters into C. elegans worms. Promoters are short sequences of the DNA strand that facilitate the transcription of the gene in that discrete region. Loss of fluorescence through the GFP gene was the marker for successful RNAi.

Several interesting mechanics were observed in the interference of GFP expression. Firstly, only those tissues that expressed the interference trigger (gfp hairpin, promoter for the GFP dsRNA transcription) exhibited loss of fluorescence, while the other tissues were not substantially silenced for GFP. This suggests cell specificity of dsRNA action through the in vivo transcription pathway, and a potential for tissue-specific interference of dsRNA. Secondly, and in the continuity of the observed specificity, the extent of silencing was dependent on the method of delivery. Exposure to extracellular nonspecific dsRNA by soaking or injection lead to RNA silencing in many more cells and their progeny, provided these cells had proper endogenous dissemination of RNA silencing signals. Thus, dsRNA introduced from exogenous sources can spread to distant tissues. This systemic silencing is thought to be related to a protective response from circulating virus, where exogenous viral dsRNA triggers the silencing of viral DNA in infected cells. Essentially, this shows that the action of RNAi is strongly related to the mode of delivery of dsRNA into an organism.

These findings are of paramount important for RNAi therapy. Doctors and researchers will have to take into account factors such as mode of delivery of dsRNA and genetic variability of the patients in trying to find the best therapeutic applications. Also, we will need methods to control for the extent and specificity of RNA silencing, especially for treatment of cancers and viral diseases, where accurate cell-targeting for gene silencing is primordial (in order to avoid silencing the genes of “healthy” cells). RNAi therapy is still at its dawn, and with much potential to be elucidated, but may bring the reward of powerful treatment against otherwise uncurable diseases.

Silent but Deadly: HIV-1 Gene Suppression

Another application for siRNA gene silencing has been HIV treatment and targeting, which Cell Journal writes about HERE.
Using a humanized mouse model, researchers at Harvard, Seoul and Germany used siRNA to target T-Cells to help combat viral replication of HIV/AIDS, as well as viral infections due to immune-suppression. The first challenge they faced was making a relevant animal model, as they didn’t want to encounter any variants that would be resistant to treatment methods due to the high diversity of sequencing in the virus.
The team used immunodeficient mice that were transplanted with human peripheral blood leukocytes, as well as some transplanted with peripheral blood mononuclear cells from an HIV-1 infected individual (Hu-PBL mice). They overcame the problem of drug-resistant variants by targeting a wide variety of host and viral proteins with siRNA that effectively prevented HIV-1 infection in the mice. The team first looked at the previous success of using antibodies to assist deliverance of siRNA into the cytoplasm of particular targeted cells, which decreases the amount of siRNA needed. They decided to use a CD7-specific single-chain antibody paired with a peptide called 9R. The CD7 antibody was chosen because it is activated by most T-cells and is internalized very rapidly, therefore making it good for siRNA delivery. The 9R peptide was chosen because it had been shown to effectively bind to polyanionic nucleic acids and can be used to deliver siRNA to neuronal cells.
In the Hu-PBL mice, treatment was conducted with a viral co-receptor called anti-CCR5 along with antiviral siRNA bonded to scFvCD7-9R. CCR5 is a chemokine receptor responsible for the fusion between the viral and host cell membranes. With these techniques, siRNA delivery helped control viral replication and prevented CD4 T-cell depletion and even restored it.
These findings help the possibility of new HIV/AIDS therapies by utilizing the receptor-targeting capabilities of siRNA delivery. The team successfully demonstrated that siRNA almost completely blocked viral protein synthesis in HIV-1 infected mice, helped restore T-cell production and suppressed viremia. Nonetheless, in order to integrate this into our current healthcare system, a lot of work still needs to be done.
For instance, delivering large quantities of the siRNA in vivo was very difficult in mice and is expected to be equally difficult in human subjects. Also, new antibodies need to be developed to target macrophages and dendritic cells also infected with HIV-1. Looking at the current pharmaceutical landscape for HIV/AIDS drugs exposes the tough competition siRNA therapy faces in the industry too. With 20 highly effective drugs available, they are administered orally and are much easier to use than the siRNA treatments. They also have years of clinical trials and human efficacy testing to back them.
However, with more clinical research I believe that protein suppression has a lot of potential to treat complex diseases like HIV/AIDS thanks to siRNA’s extremely high versatility. It can target not only the HIV virus, but also suppress acute viral infections that cause respiratory disorders, encephalitis, and hemorrhagic fever—problems that current treatments cannot dually combat. A personalized approach could trigger a paradigm shift in medicine, but costs and procedures need to be reduced and simplified, respectively, in order to integrate into our current healthcare system first.

Another excellent article on this can be found HERE

Growth inhibition of human ovarian cancer cells with siRNA

The article “Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA” by Liying Cai a, Guangmei Zhang et al. was accepted into the European Journal of Obstetrics & Gynecology and Reproductive Biology in September 2009. According to the article taken from ScienceDirect, ovarian cancer is the cause of approximately 125,000 deaths per year in the developed world. Furthermore, less than one third of the ovarian cancer patients are able to survive long term. According to Doctor Frederick Sweet from Washington University School of Medicine, there are currently several therapies for ovarian cancer, including, but not limited to, surgery and chemotherapy (1) . However, ovarian cancer can at times become easily resistant to these therapies or some “current therapies for advanced ovarian cancer are not effective enough (2)."
As a result, this article demonstrates the potential application of RNA interference as a new class of therapeutic under the scope of personalized medicine. RNA interference would be used in tumor therapy as an inhibitor of transcription 3 pathway (STAT3); the overexpressed STAT3, when active, is known to “contribute to tumorigenesis in ovarian cancer (3).” The journal article demonstrates that not only does siRNA act as an inhibitor of STAT3 cell proliferation, but also “STAT3-siRNA treatment [obviously] increased the percentage of apoptotic (death of ovarian cancer cells) cells (4)”—both highly necessary to efficiently treat cancer.
However, one must keep in mind that this study tested the inhibitor effect siRNA had on STAT3 invitro. In this preliminary stage, the study demonstrates that siRNA could potentially become a therapy for human ovarian cancer; however, more tests have yet to come to prove the efficacy of the siRNA as an inhibitor in actual patients with ovarian cancer. Nonetheless, it is important to note that there are other studies providing information on the potential benefits STAT3 inhibition, through the use of small RNA molecules, has on treating breast cancer(5) , human colon cancer (6) , etc. Therefore, as current cancer therapies’ effectiveness rates come short from meeting patients’ expectations and articles such as this one provide hope, the stronger the support and positive perception the public will have towards advancements in the use of small RNA molecules in cancer research and future treatment.
For more information go to: http://dx.doi.org and enter the following entire DOI citation in the text box provided doi:10.1016/j.ejogrb.2009.09.018

Footnotes
(1)- http://www.thedoctorwillseeyounow.com/articles/womens_health/ovarian_18/
(2)- Cai L, et al. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small
interfering RNA. Eur J Obstet Gynecol (2009), doi:10.1016/j.ejogrb.2009.09.018
(3)- C.N. Landen Jr., Y.G. Lin and G.N. Armaiz Pena et al., Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer, Cancer Res 67 (2007), pp. 10389–10396
(4)- Cai L, et al. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small
interfering RNA. Eur J Obstet Gynecol (2009), doi:10.1016/j.ejogrb.2009.09.018
(5)- Xiaoyang Ling and Ralph B. Arlinghaus, Knockdown of STAT3 Expression by RNA Interference Inhibits the Induction of Breast Tumors in Immunocompetent Mice, Cancer Research 65, 2532-2536, April 1, 2005
(6)- Yu Fan, You-Li Zhang et al., Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells, World J Gastroenterol. 2008 January 21; 14(3): 428–434.

Tumor Cell Targeting with a Little Help from siRNA

SiRNA, also known as interference RNA, is a class of double-stranded RNA molecules that has only recently been discovered and explored in depth. The main focus for much of siRNA research has been to suppress gene expression, therefore addressing the root problem for many chronic diseases directly. A recent application for this breakthrough technology has been cancer treatment and tumor cell targeting, which MIT’s Technology Review writes about HERE.
According to the article, tumor cells posses the ability to become very resistant to any cancer-destroying drugs by significantly decreasing the effectiveness of the chemotherapy process. The cells do this by undergoing mutations that do two things: they help reduce drug binding to the target cell’s membrane, and they create efflux pumps that reroute drugs directly out of the cell. The latter is accomplished by producing large amounts of P-glycoprotein that constitutes the pumps and therefore redirect the drugs without ever affecting the cell.
In order to combat the resistance, a biotech firm called EnGeneIC took bacteria cells called “minicells” that had been emptied of their DNA and replaced it with strands of siRNA, which was designed specifically to silence the gene responsible for the efflux pumps. By injecting a double strand (dsRNA), it attaches to an enzyme called a dicer which then cleaves the dsRNA into smaller pieces of siRNA. Next, the siRNA duplex attaches to another protein complex called a RISC. After unwinding, the activated RISC pairs the siRNA with the target mRNA where it is then cleaved and the protein synthesis is prevented, thus silencing the gene.
In this case the target was the P-glycoprotein gene which was responsible for producing the pumps. In addition to blocking the gene, researchers attached antibodies to the surfaces of the bacterial minicells that allowed them to adhere to markers on the tumor cells specifically and kill them. After injecting minicells intravenously into mice with aggressive forms of cancer, the study found that the mice with the minicell chemotherapy lived much longer than the control group with only standard intravenous infusion.
The advantage of siRNA treatment, as cited in the article, is that when combined with cells and target markers it possesses the ability to provide a focused attack on cells that are typically resistant to drugs. The opportunities and applications for a targeted attack are immense since drug resistance ranges from chronic disease progression to bacterial infections. However, the problem lies in the ever-increasing costs for personalized therapy. With every person containing their own distinct phenotype and gene variations, siRNA treatments must be tailor made on an individual basis, thus adding time and money. And while the article expressed that no side effects were experienced by the mice using the minicell treatment, more efficacy testing is currently underway on 96 primates, which could yield different results.
I believe the techniques expressed have a lot of potential and power, although the cost and technical factors still need to be worked out in order for a successful implementation of this therapy into our healthcare system. With appropriate communication between healthcare policy makers, physicians, and researchers, a system could be implemented that could regulate pricing per individual and cut some administrative costs. If this is achieved, it could be cheaper and much more effective to treat on an individual basis because patients would not only get healthier, but stay healthy.

RNAi - a possible solution to Hepatits B and C!

With 387 million carriers of hepatitis B virus (HBV) and 170 million people persistently infected with hepatitis C virus (HCV), we need a solution. Treatments at present include the use of drugs, interferon and anti-viral agents but none of this is very effective. However, an article from the Journal of Viral Hepatitis published on August 13,2007 shows how the discovery of RNAi and the subsequent possibility to inhibit specific viral gene expression may prove to be the treatment for Chronic Hepatitis B and C.
Several studies cited in the article have shown the efficacy of the use of RNAi against HBV in mice models. An early study showed that the most effective sequence, which targeted a region of the surface and overlapping polymerase ORF, inhibited HBV surface antigen secretion by 94% in transfected cultured cells, and 85%in vivo in the MHI model. Other more recent studies have shown that a siRNA duplex that targeted sequence nucleotides 9-27 from the surface ORF initiation codon was found to be particularly effective against HBV without a requirement for HBV DNA synthesis. In the case of HCV although early on the main target of siRNA was the 5’NTR, no efficacy was observed in later studies. Significant inhibition of virus gene expression was achieved in replicon models when targeting NS3 and NS5B sequences.
Recent studies showed that modified long hairpin RNAs (lhRNAs) have been capable of silencing hepatitis C virus targets in cell culture. This interesting observation implies that by targeting a greater viral sequence, viral escape would be minimized. Using the lhRNA approach, silencing of multiple genotypes may be possible and the probability of effective silencing by one of the several lhRNA-derived siRNAs is likely to be improved.
The main issue with the use of drugs against viruses is that the development of drugs cannot cope with the mutations of the virus. With this new approach, however, this is not the case. According to the study even though the siRNA-resistant replicons showed point mutations within the siRNA target sequence, these resistant replicons were sensitive to an siRNA that targeted another part of the genome, suggesting that use of siRNA combinations limits evolution of escape mutants. The relative ease with which potent silencing of HBV and HCV sequences can be achieved using effectors of RNAi has led to considerable enthusiasm for developing this technology for therapeutic application. This therapy is however still under study. The main concerns are Immunostimulatory Effects of Short Interfering RNAs and Expressed Hairpin Sequences, Nonspecific Interaction of Silencing Molecules with Cellular Sequences and Regulating the Dosage and also method of delivery to the target. In spite of these difficulties there is a potential for the use of RNAi as a treatment against HCV and HBV and the next few years are likely to see considerable progress in this field.
For more information and a detailed look at the article check out the link below:
Opportunities for Treating Chronic Hepatitis B and C Virus Infection Using RNA Interference
http://www.medscape.com/viewarticle/560945